Join
Live feed
·
PRReleasevia Quantisnow
BioXcel Therapeutics Inc. logo

BioXcel Therapeutics Announces FDA Approval of IGALMI™ (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults

ByQuantisnow·Wall Street's wire, on your screen.
BTAI· BioXcel Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BTAI (BioXcel Therapeutics Inc.) and more on Quantisnow.